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GaHV-2 ICP22 protein is expressed from a bicistronic transcript
regulated by three GaHV-2 microRNAs
Imane Boumart,1 Thomas Figueroa,1† Ginette Dambrine,1 Benoit Muylkens,2 Srdan Pejakovic,2 Denis Rasschaert1,*
and Catherine Dupuy1
Abstract
Herpesviruses have a lifecycle consisting of successive lytic, latent and reactivation phases. Only three infected cell proteins
(ICPs) have been described for the oncogenic Marek’s disease virus (or Gallid herpes virus 2, GaHV-2): ICP4, ICP22 and
ICP27. We focus here on ICP22, confirming its cytoplasmic location and showing that ICP22 is expressed during productive
phases of the lifecycle, via a bicistronic transcript encompassing the US10 gene. We also identified the unique promoter
controlling ICP22 expression, and its core promoter, containing functional responsive elements including E-box, ETS-1 and
GATA elements involved in ICP22 transactivation. ICP22 gene expression was weakly regulated by DNA methylation and
activated by ICP4 or ICP27 proteins. We also investigated the function of GaHV-2 ICP22. We found that this protein repressed
transcription from its own promoter and from those of IE ICP4 and ICP27, and the late gK promoter. Finally, we investigated
posttranscriptional ICP22 regulation by GaHV-2 microRNAs. We found that mdv1-miR-M5-3p and -M1-5p downregulated
ICP22 mRNA expression during latency, whereas, unexpectedly, mdv1-miR-M4-5p upregulated the expression of the protein
ICP22, indicating a tight regulation of ICP22 expression by microRNAs.
INTRODUCTION
Gallid herpes virus 2 (GaHV-2) is an oncogenic avian her-
pesvirus that causes paralysis due to the infiltration of
mononuclear cells into the peripheral nerves, and T-cell
lymphoma in chickens. Like all herpesviruses, GaHV-2 has
a lifecycle divided into lytic and latent phases, the latent
phase being associated with oncogenesis [1]. According to
the Cornell model, GaHV-2 infection in chickens is initiated
by early semi-productive cytolytic infection in B cells, peak-
ing 3 to 7 days post-infection (p.i.) in experimental condi-
tions [2]. Latency, the second major phase of the viral
lifecycle, begins at about 7 days p.i. and is characterized by
the maintenance of the viral genome without productive
replication in CD4+ T cells, resulting in oncogenesis. Viral
lytic genes are repressed during latency, whereas the viral
non-coding RNAs, including the latency-associated tran-
script (LAT) and microRNAs, continue to be expressed
[3, 4]. As reported for other herpesviruses, latent GaHV-2
in lymphocytes can revert to semi-productive cytolytic rep-
lication, in a process known as reactivation, after 2 to 3
weeks, whereas productive lytic replication occurs in the
epithelial cells of feather follicles [2].
The replication of GaHV-2 viral particles during the lytic
phase begins with the expression of three immediate early
(IE) genes conserved among alphaherpesviruses: ICP4,
ICP22 and ICP27 [1]. In all herpesviruses, the IE genes are
expressed in a classical tightly regulated temporal cascade
[5–8]. The GaHV-2 ICP22 gene is located at the 5¢ end of
the unique short (US) region, as in most alphaherpesviruses;
it encodes a 179-amino acid protein [9]. BLAST-P analysis
has shown that GaHV2-ICP22 possesses the core HERPE-
S_IE68 domain known to be well-conserved among other
previously described alphaherperviruses ICP22 [10]. This
core domain is lacking from the Iltovirus genus (GaHV-1),
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which seems to have no ICP22 homologue, despite having a
a similarly organized US region in its genome.
Initially described as an IE gene [11], GaHV-2 ICP22 has
since been shown to be a late (L) gene [12, 13]. Indeed,
whereas ICP4 and ICP27 are clearly true IE genes regardless
of the herpesvirus strain, there is no consensus regarding
the temporal pattern of ICP22 expression. Indeed, ICP22
has been described as an IE gene in HHV-1 and HHV-3,
but appears to be a non-IE gene in SuHV-1 [14] and both
an IE and L gene in BoHV-1 [15, 16].
By isolating GaHV-2 deletion mutants lacking ICP22,
ICP22 was found to be dispensable for viral replication in
cultured cells and for in vivo chicken infection by an attenu-
ated strain of GaHV-2 [13], whereas highly virulent GaHV-
2 RB-1B mutants lacking ICP22 had lower replication rates
in cultured cells but were still able to induce MD lympho-
mas, with lower rates of early cytolytic infection, tumour
incidence and mortality, suggesting a requirement of ICP22
for the lytic replication of GaHV-2, rather than latency [12].
The GaHV-2 RB-1B mutant can be reactivated from lym-
phoma-derived lymphoblastoid cell lines, demonstrating
that GaHV-2 ICP22 is dispensable for reactivation [17].
However, the precise role of ICP22 in GaHV-2 pathogenesis
remains to be determined.
HHV-1 ICP22 is the best studied of the alphaherpesvirus
ICP22 homologue. It has been shown to play an important
role in efficient viral replication and pathogenesis, through
the modulation of HHV-1 gene expression, by repressing E
gene transcription or enhancing L gene transcription [18–
20]. Most ICP22 homologues have been shown to modulate
the transcription of viral genes [16, 21], thereby affecting
the herpesvirus lifecycle. The ICP22 homologue of HHV-3
(ORF63), for example, downregulates transcription of the
homologue of ICP4, IE62, and thus plays a key role in the
establishment of latent infection [22]. The ICP22 homo-
logue of equine herpesvirus type 1 (EHV-1) can transacti-
vate EHV-1 promoters either alone or in combination with
other regulatory proteins of EHV-1, including ICP4 and
ICP27 homologues, in reporter gene assays [23]. Studies in
a heterologous system have shown that GaHV-2 ICP22
transactivates the ICP27 promoter in combination with
ICP4 [24], but this observation has yet to be confirmed in
the natural chicken system.
Completion of the GaHV-2 lifecycle requires fine-tuning of
each of the component phases. We therefore investigated
the regulation of GaHV-2 ICP4 and ICP27 expression in
more detail, as these two proteins are principally involved in
the switch between the latent and productive phases [7, 25,
26]. GaHV-2 ICP4 and ICP27, which are expressed under
the control of two alternative promoters, were specifically
downregulated by mdv1-miR-M7-5p, one of the miRNAs of
the mdv1-miR-M8-M10 cluster mapping to the first LAT
intron [25]. Indeed, as explained in the recent review by
Sorel and Dewals [27], herpesvirus miRNAs downregulate
IE transactivators, thereby restricting the lytic phase and
promoting latency and long-term persistence. In addition,
herpesvirus miRNAs may contribute to the proliferation
and transformation of latently infected cells. In this context,
GaHV-2 mdv1-miR-M4-5P, an orthologue of cellular gga-
miR-155-3P, is one of the most reliable models. The mdv1-
miR-M4-5P has been shown to downregulate the same
cellular targets as its gga-miR-155-3P orthologue, suggesting
that both may be involved in cell transformation and onco-
genesis [28, 29]. The deletion of mdv1-miR-M4 has been
shown to abolish the induction of lymphomas in chicken,
providing the first demonstration of a role for a viral
miRNA in oncogenesis in a natural model in vivo [30].
GaHV-2 mdv1-miR-M4 has also been shown to target the
viral UL28 and UL32 genes [29]. The mdv1-miR-M4 miREs
are located in coding regions, like those of mdv1-miR-M7
[25, 29], rather than in 3¢-UTR sequences, as usually
observed for animals. Moreover, the complexity of viral
miRNA functions has been highlighted in various studies
reporting the presence of viral miRNAs in HHV-4 virions,
suggesting a role in controlling the early steps of infection
[31], or that unusual targeting within the 5¢-UTR mRNA
can occur with a viral miRNA encoded by HHV-5 [32].
In this study, we characterized the GaHV-2 ICP22 gene, its
expression and regulation during the lytic, latent and reacti-
vation phases of the GaHV-2 viral cycle. We confirmed
from the finding of Parcells et al. [12, 13] that the Icp22
protein is present essentially in the cytoplasm of the infected
cells, and showed that ICP22 is expressed during the lytic
phase of the GaHV-2 lifecycle, through a bicistronic tran-
script encompassing the US10 gene. We also showed that
the expression of this gene was controlled by a unique pro-
moter, and we identified the core promoter and functional
regulatory elements. We assessed the transcriptional and
posttranscriptional regulation of ICP22 expression in more
detail. We found that ICP22 gene expression was weakly
regulated by DNA methylation. It was also activated by the
ICP4 and ICP27 proteins and repressed by ICP22 itself.
ICP22 has also been shown to act as a repressor for other
GaHV-2 genes. Finally, we investigated the targeting of
ICP22 by GaHV-2 microRNAs and showed that mdv1-
miR-M5-3p and –M1-5p downregulated ICP22 expression,
as generally observed, whereas, surprisingly, mdv1-miR-
M4-5p upregulated ICP22 expression.
RESULTS
ICP22 expression is associated with the lytic phase
of the lifecycle
We first investigated the intracellular distribution of ICP22
by staining RB-1B GaHV-2-infected chicken embryo fibro-
blasts (CEF RB-1B) and MSB-1 cells latently infected with
GaHV-2 with an anti-ICP22 polyclonal antiserum. In paral-
lel, we used mAb 3F19, directed against the major capsid
protein VP5 [33], which is produced exclusively during the
lytic and reactivation phases (Fig. 1a). In CEF RB-1B cells,
corresponding to the lytic phase of infection, ICP22 was
detected mostly in the cytoplasm of the infected cells,
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whereas, as expected, the major capsid protein VP5 was
found exclusively in the nucleus. In latently infected MSB-1
lymphocytes, ICP22 was found only in the cytoplasm of
cells expressing VP5 representing naturally reactivated cells
(approximately 1% of total cells).
We estimated ICP22 mRNA levels during the lytic and
latent phases of the GaHV-2 cycle, by quantitative RT-PCR
with the B264/A962 primer pair, on total mRNA extracted
from MSB-1 cells, MSB-1 cells treated with sodium n-buty-
rate (MSB-1R) to induce reactivation of the latent virus, and
CEF RB-1B cells. We found that ICP22 was transcribed
exclusively during lytic phases, with mRNA levels during
the lytic phase proper 2.5 times higher than those during
reactivation (Fig. 1b). The very low levels of ICP22 tran-
script in latently infected MSB-1 cells is consistent with pre-
vious immunofluorescence (IF) observations that revealed
ICP22 to be present only in MSB-1 cells in which the latent
GaHV-2 virus had been naturally reactivated.
ICP22 is a part of a lytic bicistronic transcript
We characterized the ICP22 mRNA, by 5¢ and 3¢ RACE on
the total RNA extracted from MSB-1 cells, MSB-1R and
CEF RB-1B cells. Six independent libraries were constructed
in pGEMTeasy, by cloning the 5¢ and 3¢ RACE PCR prod-
ucts amplified with the A960 primer binding 41 nt
Fig. 1. Expression of ICP22 in cells with lytic or latent infection. (a) Cellular distribution of ICP22 in CEF RB-1B and MSB-1 cells. ICP22
proteins were labelled with polyclonal antibodies against ICP22 and Alexa Fluor 594–goat anti-rabbit IgG (red), and VP5 was labelled
with the anti-VP5 mAb 3F19 and Alexa Fluor 488–goat anti-mouse IgG (green). Cell nuclei were stained with Hoechst stain (top). (b)
Relative levels of ICP22 mRNAs in MSB-1 cells, MSB-1 cells treated with 3mM sodium n-butyrate (MSB-1R) and RB-1B-infected CEFs
(CEF RB-1B). Total RNA was isolated for reverse transcriptase (RT)-qPCR with the B264-A962 primers. The relative levels of ICP22
mRNA were determined by the 2 DDCt method, with normalization relative to GAPDH mRNA. The reported values are expressed rela-
tive to that for CEF RB-1B, arbitrarily set to 1. The histograms correspond to the mean of triplicates for two independent experiments.
Standard errors are shown. Significant differences in expression are indicated with asterisks (**), for Student’s t-test P-value<0.01.
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downtream from the start codon and the A478 primer bind-
ing 131 nt upstream from the ICP22 stop codon, respec-
tively. We sequenced 50 clones from each library. For 5¢
RACE PCR, we identified two TSSs: a major TSS155440 41 nt
upstream from the ICP22 start codon, which was found in
70 to 75% of the clones of the three cell lines, and a minor
site, TSS155424, located 16 nt upstream from the major TSS.
The major TSS corresponds to adenosine A 155440 of the
RB-1B genome, the first adenosine residue of a canonical
predicted initiator element (Inr) TTACACT (Fig. 2a).
For 3¢ RACE we identified two 3¢ end sites. The very minor
site (nt 156289) located 12 nt downstream from an
ATTAAA polyA signal was found in only one clone of the
MSB-1R and RB-1B-infected CEF libraries (Fig. 2a). The
use of this minor site would lead to the production of
an mRNA specific to ICP22. The second 3¢ end site
Fig. 2. Characterization of the transcripts encoded by the ICP22 and US10 locus. (a) Schematic diagram of the TRL/TRS regions of the
GaHV-2 RB1B strain genome (GenBank accession no. EF523390.1) (top), expanded to show a part of the US region (155130–157014) in
detail. Black arrows show the predicted ORF; the numbers indicate the location relative to the GaHV-2 RB-1B genome. Bottom: identifi-
cation of the 3¢ (AAA) and 5¢ ends of ICP22 byh RACE-PCR with RNA extracts from MSB-1 cells, MSB-1 cells after reactivation with
3mM sodium n-butyrate (MSB-1R) and CEF RB-1B cells. White and grey arrows indicate the positions of the primers used for 3’¢RACE-
PCR (A478) and for 5¢ RACE-PCR (A960), respectively. The position of the predicted polyA signal is indicated. (b) Identification, by semi-
quantitative RT-PCR, of ICP22-US10, with the A966 and B152 primers, GAPDH and VP5 transcripts in unifected CEFs, CEF RB-1B, MSB-
1 and MSB-1R cells. (c) Identification, by semi-quantitative RT-PCR, of ICP22, US10 and ICP22-US10 GAPDH and VP5 transcripts from
RNA extracts from the peripheral blood leukocytes of chickens infected with RB1B for 28 days, on days 0 (D0), 7 (D7), 14 (D14), 21
(D21) and 28 (D28). Left: migration of the 488 bp amplicon (primers A474-B068), the 614 bp amplicon (primers B263-B152), the 537 bp
amplicon (primers A966-A967), the 283 bp amplicon for VP5 (432–433 primers) and the 220 bp amplicon for GAPDH (primers M450–
M451). Right: ratios of each band of the RT-PCR products obtained in RB-1B-infected CEF were determined by comparing the relative
peak areas of the amplifications, with Adobe Photoshop 6 standardized with those obtained with GAPDH and normalized with respect
to VP5. The intensity of each fragment was standardized according to amplicon length and the intensity of the band corresponding to
GAPDH, and normalized against VP5, for which the value was arbitrarily set to one. Error bars indicate the SEM for three independent
biological experiments.
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(nt 157010), found in all the other sequenced clones, is
located downstream from the US10 stop codon, 19 nt down-
stream from a canonical AATAAA polyA signal (Fig. 2a).
Finally, RT-PCR on the total RNA extracted from the three
types of cells with the A966 and B152 primers encompass-
ing both ICP22 and US10 confirmed the presence of ICP22
and US10 in a large bicistronic transcript during the lytic
and reactivation phases (Fig. 2b).
For confirmation of these data in vivo, we carried out a set
of three semi-quantitative PCRs on total RNA extracted
from peripheral blood leucocytes (PBLs) collected at 0, 7,
14, 21 and 28 days p.i. from chickens infected with GaHV2
RB-1B using CEF RB-1B as a control. The A966 and A967,
B263 and B152, and A474 and B068 primer pairs were used
for more specific amplification of the ICP22 and US10 genes
and the bicistronic mRNA, respectively, yielding amplicons
of similar length (Fig. 2c). The levels of ICP22, US10 and the
bicistronic mRNA differed significantly between lytic phases
of infection (7 and 28 days p.i.) and the latent phase of viral
infection (14 and 21 days p.i.) (Fig. 2c). The very weak
bands on electrophoretic gels at 14 and 21 days p.i. may
reflect the viral reactivation classically reported in this in
vivo model. The intensity of each band for RB-1B-infected
CEFs was standardized with respect to a band correspond-
ing to GAPDH amplified with the GAPDH-F and GAPDH-
R primers and normalized with respect to VP5 (Fig. 2c). No
significant differences were observed between the three
amplicons. We therefore conclude, consistently with our 3¢
RACE results, that the ICP22 and US10 transcripts were
essentially produced as a single bicistronic mRNA during
the lytic phase of the viral cycle.
The ICP22 core promoter is controlled by at least
seven response elements
We characterized the ICP22 core promoter, with a nested
set of four truncated constructs encompassing the 1000 nt
upstream from TSS155440. The 1000, 800, 500, 200 and 100
nt immediately upstream from the start codon were ampli-
fied and inserted into the pGL3-basic vector to obtain the
pICP22-1000, pICP22-800, pICP22-500, pICP22-200 and
pICP22-100 constructs, respectively (Fig. 3a). MSB-1 cells
were cotransfected with these promoter constructs, the
pGL3-basic vector (negative control) or pcDNA-MLuc
(positive control sharing the CMV promoter), together with
the pRL-TK vector (Renilla luciferase), and the resulting
promoter activity was assessed in luciferase assays. The ratio
of firefly/Renilla luciferase activities for each template was
arbitrarily expressed relative to that for the longest construct
(pICP22-1000). Unlike the pGL3-basic control and pICP22-
100, the other four promoters were efficient (Fig. 3a), with
pICP22-200 having the highest levels of activity, 46% that
of the standard CMV promoter of pcDNA-MLuc (data not
shown). We therefore identified pICP22-200 as the minimal
functional core promoter.
In silico analysis of the pICP22-200 core promoter with
Genomatix software revealed the presence of response ele-
ments (REs) for basal transcription, TATA and GC boxes,
and five REs potentially involved in the regulation of gene
transcription during haematopoiesis, an Ebox, GATA box
and REs for Oct-1, CRE and Ets-1. The seven predicted REs
were mutated separately in the pICP22-200 core promoter
construct. The resulting constructs were used to transfect
MSB-1 cells and the corresponding measured luciferase
activities were standardized against the native pICP22-200
(Fig. 3b). All seven REs seemed to be involved in ICP22 pro-
moter activity. The TATA and GATA boxes, and the ETS-
1RE, E-box and GC box, mutations of which decreased
luciferase activity significantly, by 27, 47, 55, 91 and 32%,
respectively, were involved in the activation of ICP22 tran-
scription, whereas, Oct-1 and CRE, mutations of which
increased luciferase activity by 29 and 43%, respectively,
were involved in its repression.
The ICP22 core promoter is not regulated by DNA
methylation
We investigated pICP22-200 promoter methylation by
bisulfite genomic sequencing analysis (BGSA) of viral geno-
mic DNA extracted from MDV-infected cells in the three
phases of the viral lifecycle: MSB-1 cells (latency), MSB-1
cells treated with 5-azacytidine (MSB-1R) for reactivation
and RB-1B-infected CEFs (lytic phase) (Fig. 3c). The five
cytosine/guanine (CpG) dinucleotides of the pICP22-200
promoter were unmethylated (MSB-1 cells) or slightly
methylated (MSB-1R and CEF RB-1B), with the RE USF-1
Ebox, in particular, being methylated during the reactiva-
tion phase (28%) and the lytic phase (14%).
ICP22 gene expression is regulated by three GaHV-
2 miRs
An internal BLAST search predicted the presence of three
potential miRNA responsive elements (miREs), for mdv1-
miR-M5-3p, mdv1-miR-M4-5p and mdv1-miR-M1-5p,
within the ICP22 ORF. There was a miRE-M5-3p (position
155496–155518) 15 nt upstream from the start codon, a
miRE-M1-5p (position 155786–155807) 656 nt upstream
from the start codon, and a miRE-M4-5p (position 155998–
156020) spanned the stop codon (Fig. 4a). The relative
expression levels of the three miRNAs mdv1-miR-M5-3p,
mdv1-miR-M4-5p and mdv1-miR-M1-5p, in CEF RB-1B,
MSB-1 and MSB-1R cells, have been estimated from the
RNA extracted for the determination of the ICP22-mRNA
level of the Fig. 1, by specific RT-qPCRs with the primers
M1-5p, M4-5p and M5-3p, respectively (Fig. 4b). The
expression of mdv1-miR-M1-5p was significantly reduced
(five times) during the reactivation phase. The expression of
mdv1-miR-M4-5p increased threefold in the latently
infected MSB-1 cells. Lastly, mdv1-miR-M5-3p, which was
16 times more expressed in MSB-1 than in lytic-infected
CEF RB-1B cells, was very weakly detected during the reac-
tivation phase.
We investigated the functions of the miREs, by inserting the
predicted ICP22 ORF into the pcDNA3.1 expression vector,
to generate pcICP22 and three mutants constructs: pcICP22-
miRE-M1m, pcICP22-miRE-M5m and pcICP22-miRE-M4m
Boumart et al., Journal of General Virology 2018;99:1286–1300
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Fig. 3. Characterization of the ICP22 promoter. (a) Characterization of the core promoter of ICP22 in MSB-1 cells. Schematic diagram
of the four promoter deletion constructs inserted downstream from the firefly gene (Luc) in the pGL-3 Basic vector, with numbers indi-
cating nt positions relative to the RB-1B genome (GenBank accession no. EF523390.1). Promoter activity was assessed by measuring
luciferase assay after the transfection of MSB-1 cells. Data are expressed relative to luciferase activity after arbitrary normalization
against the pICP22-1000 promoter, for which the value was set to 1. Error bars indicate the SEM for three independent biological experi-
ments performed in triplicate (n=3). *P<0.05 in Student’s t-test. (b) Identification of the response elements (REs) involved in regulation
of the pICP22-200 core construct. The REs identified in silico with Genomatix software are indicated by grey shapes, and the mutated
REs are indicated by darker shapes. The promoter activities of the mutated-RE constructs were assessed in luciferase assays on
MSB-1 cells. Luciferase activities were normalized with respect to that for pICP22-200, set to 1. Error bars indicate the SEM for three
independent biological experiments performed in triplicate. *Student’s t-test P-value<0.05 versus pICP22-200 and ** P-value<0.001 ver-
sus pICP22-200. (c) DNA methylation of the pICP22-200 promotor. Methylation status of CpG islands (CGI) in the pICP22-200 promoter
region, determined in three cell conditions: MSB-1, MSB-1 treated with 5-azacitidine (MSB-1R) and CEF RB-1B. The white rectangles
correspond to the CGIs identified in this region, according to the TSS2 annotation. The unmethylated CGIs are shown as white rectan-
gles/boxes, methylated CGIs are indicated by black rectangles. The mean percent methylation is indicated by the black rectangles.
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Fig. 4. Targeting of ICP22 by mdv1-miR-M5-3p and mdv1-miR-M1-5p. (a) Localization of the miRE-M5-3p, miRE-M1-5p and miRE-M4-
5p in ICP22 gene. The position of each miRE is indicated. (b) Relative expression of mdv1-miR-M1-5P (white), mdv1-miR-M4-5P (grey)
and mdv1-miR-M5-3P (black), in CEF RB-1B, MSB-1 and MSB-1R cells as determined by RT-qPCR with the 2 (DDCt) method using
U6snRNA as the reference. Error bars of two independent experiments carried out in triplicate are shown. For each miR, the values
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(Figs 4b and 5a). As miRE-M4-5p spanned the stop codon, we
took care to ensure that the UAA codon was conserved in the
pcICP22-M4m construct (Fig. 5a). These constructs were
used to contransfect GaHV-2-free cells (DF-1 cells), with
pcDNA-mdv1-miR-M1, pcDNA-mdv1-miR-M5 or pcDNA-
mdv1-miR-M4, each expressing the premiR, or native
pcDNA.3.1 as a negative control. Total RNA was extracted
from the DF-1 cells 48 h after transfection, and ICP22 mRNA
levels were estimated directly, by RT-qPCR. Mutations of
miRE-M5-3p and miRE-M1-5p were associated with signifi-
cant increases in ICP22-mRNA level, of 2.8- and 2.4-fold,
respectively (Fig. 4d, e). Surprisingly, the mutation of miRE-
M4-5p decreased ICP22 mRNA levels by about 50%,
revealing a positive impact of mdv1-miR-M4-5p on ICP22
expression (Fig. 5b). For confirmation of these findings, we
repeated the previous experiment, by cotransfecting pcICP22
(wt) and pcICP22-miRE-M4m, respectively, with pcDNA-
mdv1-miR-M4, pcDNA-gga-miR-155 (expressing the cellular
miR orthologous to mdv1-miR-M4-5p), pcDNA-mdv1-miR-
M8 (expressing mdv1-premiR-M8) or native pcDNA.3.1,
used as negative controls (Fig. 5b). Interestingly, an effect on
ICP22 mRNA levels similar to that observed with mdv1-miR-
M4 was also seen with gga-miR-155 on miRE-M4m (Fig. 5b).
We checked the impact of mdv1-miR-M4-5p and gga-miR-
155-5p on ICP22 protein levels, by performing Western
blots with polyclonal antiserum against ICP22 and an anti-
GAPDH MAb as a control, on proteins extracted from cells
cotransfected with the related miRs and miREs as previously
described.
Consistent with the RT-qPCR data shown above, the pres-
ence of the ICP22 protein was found to be dependent on the
simultaneous presence of mdv1-miR-M4 or gga-miR-155
and a functional miRE-M4-5p (Fig. 5c, d). Moreover, we
detected no ICP22 protein in cells cotransfected with mdv1-
miR-M5-3p and mdv1-miR-M1-5p (data not shown), sug-
gesting that mdv1-miR-M4 may be required for ICP22
expression.
ICP22 represses the expression of some viral
genes
We investigated the regulation of the ICP22 promoter by
GaHV-2 proteins, by using the pcICP22, pcICP4, pcICP27
and pcVP16 constructs to cotransfect DF-1 cells with
pICP22-1000 in luciferase reporter assays, with pcDNA.3.1
as a control (Fig. 6a). The ectopic expression of ICP27 and
VP16 had no effect on levels of transcription from the
ICP22 promoter, whereas ICP4 and ICP22 had a significant
impact, triggering an increase in promoter activity of 29%
and a 52% decrease in promoter activity, respectively
(Fig. 6a).
Finally, we investigated the effect of ectopic ICP22 expres-
sion on various viral promoters in a luciferase reporter assay
on DF-1 cells cotransfected with pcICP22 and the pICP22-
200, pICP27-1000, pICP4-dis, pgK-1000 and pcDNAMluc
constructs, in which the promoters of ICP22, ICP27, ICP4
and gK were cloned upstream from the luciferase gene of
the pGL3 vector. ICP22 significantly reduced the activity of
all the promoters tested, including IE promoters (pICP22-
1000, pICP27-1000 and pICP4-dis), late promoters (pgK-
1000) and the CMV promoter (pcDNAMluc) (Fig. 6b).
DISCUSSION
ICP22 is common to all members of the Alphaherpesvirinae
other than Iltovirus [34]. We describe here the characteris-
tics of the ICP22 of the oncogenic alphaherpesvirus GaHV-
2, including the dependence of its expression of viral
lifecycle phase. Like the ICP22s of most alphaherpesviruses,
including that of HHV-1 [35], and unlike the homologous
protein of HHV-3 (IE68), which is transcribed during
latency [36], we confirm here, that the ICP22 gene and the
corresponding protein are expressed during the lytic and
reactivation phases (Fig. 1), but not during latency as previ-
ously reported [12, 17, 37]. Moreover, we showed that the
transcription profiles of ICP22 and of the major capsid gene
VP5, characteristic of the lytic phases of the viral cycle, are
identical in vitro, in CEF RB-1B and in MSB-1R, and in
vivo, in PBLs collected from RB-1B-infected chickens with
high levels of expression on days 7 and 28 p.i. (initial and
late lytic productive phases, respectively) (Fig. 2c), poten-
tially corresponding to the spontaneous viral reactivation
classically observed in our in vivo model. Finally, it should
be noted that this transcription during the lytic phases of
GaHV-2 infection differentiates ICP22 from the other two
ICP genes, ICP4 and ICP27, which are transcribed during
both lytic phases and latency [7, 26].
are standardized to CEF RB-1B values, arbitrarily set to 1. Significant differences in expression are indicated with asterisks (**), for
Student’s t-test P<0.01. (c) The sequence complementarity of mdv1-miR-M5-3p (left), and mdv1-miR-M1-5p (right) and their predicted
miREs identified in the ICP22 sequences of the GaHV-2 RB1B genome are shown. The microRNA seed region is highlighted in black
(: denotes wobble pair G-U, I denotes Watson–Crick pair); bars indicate nucleotides complementary between the miR and the corre-
sponding miRE. ICP22-miRE-M5m and ICP22-miR-M1m are the sequences of the related mutated miRE with the changed nucleotide
and complementarities. (d–e) Downregulation of the ICP22 transcript by mdv1-miR-M5-3p and mdv1-miR-M1-5p. DF-1 cells were
cotransfected with pcDNA constructs, pcICP22 (ICP22wt) or pcICP22 with a mutated miRE-M5-3p (miRE-M5m) or miR-M1-5p (miRE-
M1m), and with miRNA expression vector: pcDNA-mdv1-miR-M5-3p, pcDNA-mdv1-miR-M1-5p, or the empty pcDNA vector as a control.
Total RNA was extracted and subjected to RT-qPCR. ICP22 transcript levels were calculated relative to those of GAPDH. ICP22 mRNA
levels were quantified by the RT-qPCR 2 DDCt method, with GAPDH mRNA as the reference. The histograms show the mean of tripli-
cates of two independent lipofections of DF-1 cells. ICP22 mRNA levels were normalized relative to those after transfection with
pCDNA3.1. * Student’s t-test, P-value<0.05 versus pCDNA3.1.
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As in most alphaherpesviruses the ICP22 genes of GaHV-2
have been shown to be located at the 5¢ end of the unique
short US region [9]. We confirmed, by 5¢ and 3¢ RACE, that
the 1.7 kb mRNA initially identified on Northern blots and
in targeted deletions contains the ICP22 transcript [11, 13].
We characterized this mRNA as a 1587 nt bicistronic tran-
script (from TSS155440 to the beginning of the polyA
domain, positions 155442 and 157089, respectively)
Fig. 5. Targeting of ICP22 by mdv1-miR-M4-5p. (a) The sequence complementarity of mdv1-miR-M4-5p (left) and gga-miR-155 (right)
and the predicted miRE-M4wt identified in the ICP22 sequences of the GaHV-2 RB-1B genome are shown. The microRNA seed region
is highlighted in grey (: denotes wobble pair G-U, I denotes Watson–Crick pair); bars indicate nucleotides complementary between the
miR and the corresponding miRE. ICP22-miRE-M4m is the sequence of the related mutated miRE with the changed nucleotide and
complementarities. (b) Upregulation of the ICP22 transcript by mdv1-miR-M4-5p and gga-miR-155. DF-1 cells were cotransfected with
pcDNA constructs pcICP22 (ICP22-wt) or pcICP22 mutated for miRE-M4-5p (miRE-M4m), and with miRNA expression vector: pcDNA-
mdv1-miR-M4-5p, pcDNA-gga-miR-155, pcDNA-mdv1-miR-M8 or empty pcDNA vector as the control. Total RNA was extracted and
subjected to RT-qPCR. ICP22 transcript levels were calculated relative to those of GAPDH. ICP22 mRNA levels were quantified by the
RT-qPCR 2 DD Ct method, with GAPDH mRNA as the reference. The histograms show the mean of triplicates of two independent lipo-
fections of DF-1 cells. ICP22 mRNA levels were normalized relative to those obtained after transfection with pCDNA3.1. * Student’s t-
test, P-value<0.05 versus pCDNA3.1. (c–d) Western blot analysis of the upregulation of ICP22 by mdv1-miR-M4-5p. DF-1 cells were
cotransfected with pcDNA constructs pcICP22 (ICP22-wt) or pcICP22 mutated for miRE-M4-5p (miRE-M4m), and with miRNA expres-
sion vector: pcDNA-mdv1-miR-M4-5p, pcDNA-gga-miR-155 (c), pcDNA- mdv1-miR-M8 or empty pcDNA vector as the control (d). Pro-
teins were extracted and immunodetected with polyclonal anti-ICP22 (green) or monoclonal anti-GAPDH antibodies (red). Brackets
indicate the expected position of the different forms of ICP22.
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encompassing the ICP22 and US10 genes (Fig. 2a). Our data
suggest that ICP22 and US10 share an AATAAA polyadeny-
lation signal downstream from the US10 gene (position
157010) [12, 13]. This sharing of a single polyadenylation
signal by more than one gene, which is very common in
alphaherpesviruses, has already been reported for the US
and UL regions of GaHV-2, for the US7 (gI), and US8 (gE),
UL53 (gK) and UL54 (ICP27) genes, respectively [26, 38]. In
addition, a previous study showed that two other mRNAs
(2.6 and 0.9 kb) transcribed from the 5¢ region of US are
more weakly detected than the 1.7 kb mRNA by a probe
covering the ICP22 and US10 genes [12]. By 5¢ RACE
specific for the SORF2 and US10 genes on RNA extracted
from RB-1B CEFs and n-butyrate-treated MSB-1 cells, we
also identified two major TSSs, 128 nt (position 154647)
and 55 nt (position 156254) upstream from the two genes,
respectively. The use of these sites, together with the
157010-AATAAA polyadenylation would lead to the pro-
duction of mRNA molecules of 2360 nt and 780 nt in length
(data not shown). However, we can not exclude that the
0.9 kb mRNA instead could correspond to a weakly
expressed monocistronic ICP22 mRNA of 849 nt, beginning
at the TSS155440 and ending at the lower efficiency polyade-
nylation signal 156289-ATTAAA site, which we have found
to be very poorly functional.
The transcription of both mono- and bicistronic ICP22
mRNAs is driven by a single promoter, including a core
promoter located within the 200 nt immediately upstream
from TSS155440. These characteristics are consistent with the
description of classical major IE herpesvirus promoters,
which commonly include functional ubiquitous REs, such
as CRE, TATA and GC boxes [39]. In addition, the three
most effective REs – the GATA box, E-box and ETS-1 REs
Fig. 6. Impact of ectopically expressed GaHV-2 immediate early proteins on IE and L genes’ promoter activity. (a) DF-1 cells were
cotransfected with the pICP22-200 reporter vector with the pcDNA ICP expression vector (pcICP22, pcICP4, pcICP27), the pcDNA VP16
expression vector (pcVP16) or an empty pcDNA3.1 vector. Promoter activities were normalized with respect to the corresponding
empty pcDNA3.1 vector (standardized to 1). (b) Effect of ICP22 ectopic expression by cotransfection of pcICP22 with pGL3 plasmids
containing the promoter sequences of ICP22, ICP27, ICP4 and gk (pICP22-200, pICP27-1000, pICP4-dis, pgK-1000) in DF-1 cells. Error
bars indicate the SEM for three independent biological experiments performed in triplicate (n=3). (**) indicates significant values
P<0.05 in Student’s t-test.
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– mutations of which reduced luciferase activity by up to
50% (Fig. 3b), have classically been implicated in lympho-
magenesis and the viral infection of lymphocytes. In
particular, the transactivator ETS-1 is essential for lymphan-
giogenesis due to HHV8 and for EBV HHV4 lymphoma-
genesis [40, 41]. Together with USF-1, it is involved in the
transcriptional activity of HIV in T lymphocytes [42]. In
addition, ICP4 is the only one of the four overexpressed
viral transactivators to enhance ICP22 transcription signifi-
cantly, consistent with a role as a major early activator. As
observed for the other two ICPs of GaHV-2 (ICP4 and
ICP27) [7, 26], the absence of an effect of the VP16 of
GaHV-2 on the transcription of ICP22 provides support for
a non-essential role of this protein in virus growth
in vitro [43].
Unlike the other two GaHV-2 ICP genes, which are regu-
lated by dual promoters at the transcriptional level and by
alternative splicing at the posttranscriptional level [7, 26],
expression of the GaHV-2 ICP22 gene is regulated by a sin-
gle promoter, to generate an unspliced transcript. Contrast-
ing again with ICP27 and ICP4, the viral phase-dependent
expression of ICP22 seems to be unrelated to the methyla-
tion level of the promoter (Fig. 3c). The light methylation of
the ICP22 promoter, regardless of viral cycle phase, is con-
sistent with published data reporting only weak methylation
of this genomic region of GaHV-2 [17, 44]. As no methyla-
tion was detected during latency, and only the E-box was
slightly methylated during the reactivation or lytic phases
when ICP22 is transcribed, epigenetic methylation may be
involved in fine-tuning the expression of ICP22 during lytic
infection or reactivation.
Conversely, miR-mediated epigenetic regulation of ICP22
expression seems to be essential. Two viral miRs,
expressed more strongly in tumours than in GaHV-2-
infected CEFs [45], mdv1-miR-M1-5P and mdv1-miR-
M5-3P, had typical effects. The binding of these two miRs
to their miREs in the ORF, decreased ICP22 mRNA levels
by a factor of about 2.5 in DF-1 transfected cells (Fig. 4).
By contrast, in a similar experiment, the binding of mdv1-
miR-M4-5P and of the orthologous cellular miR gga-mir-
155-3p to the stop codon overlapping miRE-M4 leads to
an increase in ICP22 mRNA levels, and would be strictly
required for production of the protein in productive cells
(Fig. 5). We suggest, that in latently infected MSB-1 lym-
phocytes, the effect of mdv1-miR-M4-5p could be abol-
ished by mdv1-miR-M1-5P and especially the strong
expression of mdv1-miR-M5-3p (Figs 1b and 4b). These
last two miRs, may also fine-tune ICP22 expression during
the lytic phases of the infection and in GaHV-2-infected
CEFs, in which they are weakly expressed. Finally, these
data add to those of our previous studies, showing that
mdv1-miR-M7-5p and mdv1-miR-M4-5P target the other
two GaHV-2 ICP genes (ICP4 and ICP27) and two late
genes (UL28 and UL32), respectively, demonstrating the
ability of viral miRs to regulate both the latent and lytic
phases of the lifecycle [26, 29].
An analysis of all published miR libraries, in which mdv1-
miR-M4-5P is one of the two most strongly expressed miRs
both during lytic phases and latency [45–48], strongly sug-
gested that this molecule is a key miR for GaHV-2 replica-
tion in vivo and in vitro. In addition, a previous study
showed that mutations of the mdv1-miR-M4 seed sequence
led a loss of GaHV-2 oncogenicity, and that mdv1-miR-
M4-5P could be replaced by gga-mir-155 in the viral
genome with no significant effect on tumour induction [30].
Moreover, the authors reported that oncogenesis required
the presence of other miRs from the mdv1-miR-M4-M9
cluster, such as mdv1-miR-M5. However, as mdv1-miR-
M4-5P accounts for 70% of the viral miRs expressed in vivo
in libraries established from PBLs and feather follicles of
chickens infected with the non-oncogenic strain CVI-988
(data not shown), we suggest that it probably also plays a
major role in the lytic phase of GaHV-2, possibly by upre-
gulating ICP22.
We were able to identify only two published examples of
translational enhancement resulting from the direct interac-
tion of a miR with the targeted mRNA. Specifically, the
binding of hsa-miR-10a and hsa-miR-122 to their miRE in
the 5¢-UTR region of ribosomal proteins and of the HCV
genome, respectively, allows translation [49, 50]. Our
model, in which the binding of mdv1-miR-M4-5P and gga-
mir-155-3P to the ICP22 stop codon affects both the
amount of mRNA produced and its translation, seems to
correspond instead to a possible new example of nonsense-
mediated mRNA decay (NMD)-based immunity. NMD was
initially described as an RNA surveillance mechanism
responsible for eliminating aberrant transcripts containing
premature termination codons (PTCs), but it is also
involved in the regular negative control of 3 to 20% of genes
[51]. The presence of ORFs in the 3¢-UTR or an atypically
long 3¢-UTR facilitates the downregulation of these normal
mRNAs by NMD. A bioinformatic analysis of the human
RefSeq transcriptome showed that only a few unspliced
bicistronic eukaryotic transcripts are translated, and that
these transcripts use various strategies to escape NMD [52].
We suggest that the unspliced bicistronic transcript of
ICP22, which contains a long 3¢-UTR encompassing the
US10 ORF, is likely to be controlled by NMD (Fig. 2). In
addition, based on our data, showing that the translation of
ICP22 from the monocistronic construct (pICP22) is also
dependent on mdv1-miR-M4-5P or gga-mir-155-3P
(Fig. 5), we presume that the binding of mdv1-miR-M4-5P/
Ago2 to the stop codon would increase mRNA levels, mak-
ing it possible to generate ICP22 protein. These hypotheses
are currently being tested, by assessing the stabilization of
NMD-targeted cellular transcripts by miR-mediated gene
silencing through microarray approaches that have identi-
fied 45 monocistronic and nine bicistronic transcripts of
HeLa cells displaying downregulation, by a factor of two to
three, on Ago2 silencing [53]. Moreover, the binding of the
miR/Ago2 complex close to the stop codon would result in
a direct interaction of Ago2 with the cap, leading directly to
eIF4E-dependent translation without the pre-scanning by
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CBP80/20-dependent translation classically observed during
nuclear mRNA export [53].
We showed, by expressing ICP22 ectopically in DF-1 cells
not infected with GaHV-2, that the GaHV-2 ICP22 downre-
gulates the transcriptional activity of the five promoters
tested: its own promoter, the promoters of the two IE genes
ICP27 and ICP4, and those of gK and CMV present in
pcDNAMluc (Fig. 6b). These data are consistent with find-
ings for HHV-1, HHV-3, SuHV-1 and BoHV-2 [16, 21, 54–
56], showing that ICP22 decreases the transcription of genes
in a cell type-specific manner, possibly by regulating the
phosphorylation of RNA polymerase II, as in HHV-1 [35].
This intrinsic function, which is conserved among herpesvi-
rus ICP22 proteins, is supported by an alignment of the cor-
responding protein, which showed there to be 36% identity
in the IE_68 domain (Fig. S1, available in the online version
of this article). In addition, the ICP22 of mardiviruses is
shorter than that of the other alphaherpesviruses [10]. It
consists essentially of the IE_68 domain, without the long
NH2 and COOH terminal repeat sequences carrying the
nuclear localization signals found in other alphaherpesvi-
ruses which drive the nuclear localization of ICP22 in the
HHV-1, HHV-3 and SuHV-1 models [57–61]. These obser-
vations may reflect former findings, confirming here that
the ICP22 protein is detectable mainly in the cytoplasm of
GaHV-2-infected cells (Fig. 1a) despite its transactivator
activity, suggesting that ICP22 is imported to the nucleus
independently of the presence of an NLS [12, 17]. Such
observations have also been described for ICP4 and for the
viral phosphorylated GaHV-2 pp38, ICP22 appearing asso-
ciated to pp38 at distinct cytoplasmic sites [7, 12, 17]. Sev-
eral NLS-independent mechanisms may mediate nuclear
import [59]: transport through alternative carriers, as
reported for the transport of the VP5 of HHV-1 by VP22a
[58], direct nuclear import through passive diffusion for
proteins with molecular mass of up to 40 kDa [59] or phos-
phorylation/dephosphorylation coupled to translocation to
the nucleus with an NLS-independent mechanism may
account for ICP22 nuclear import [56, 60]. Finally, we can-
not rule out that a small undetectable amount of ICP22 is
imported to the nucleus at a rate driving promoter activity.
Further investigations are required to precisely establish the
mechanism whereby GaHV-2 ICP22 is transported into the
nucleus.
In conclusion, we studied the transcriptional and posttran-
scriptional regulation of ICP22, the third and last GaHV-2
ICP gene. ICP22 is expressed exclusively during the lytic
phases of viral infection in vivo and in vitro. This pattern of
regulation contrasts strongly with that of the other two
ICPs. The transcription of the unspliced ICP22 mRNA is
driven by a single promoter that is not regulated by methyl-
ation. As observed for ICP4 and ICP27, the expression of
ICP22 is regulated by viral miRs. However, whereas mdv1-
miR-M1-5P and mdv1-miR-M5-3p act like mdv1-miR-M7-
5P for ICP4 and ICP27, reducing the level of ICP22 mRNA,
the binding of mdv1-miR-M4-5P to the stop codon seems
to be required for production of the ICP22 protein. Finally,
we propose a very preliminary model, in which ICP22
expression is promoted initially by the expression of gga-
mir-155-3P in PBLs and then by mdv1-miR-M4-5P in
infected PBLs, in which gga-mir-155-3P is repressed [29].
As shown for HHV-1 [61], ICP22 could shut off the tran-
scription of cellular genes during the lytic phase and reacti-
vation. As mdv1-miR-M4-5P is strongly expressed during
all phases of infection, ICP22 would be repressed by RNA
interference due to mdv1-miR-M1-5P and the overex-
pressed mdv1-miR-M5-3P during latency, allowing latently
infected cells to survive. Further studies are currently under-
way to confirm this putative model and to increase our
understanding of the fine mechanism involved in the direct
positive epigenetic regulation of a protein by a single miR.
METHODS
Virus strain and cell cultures
The latently infected MSB-1 cell line, derived from a spleen
lymphoma induced by a virulent strain of GaHV-2 [62],
was maintained in RPMI 1640 medium (Lonza) supple-
mented with 1mM sodium pyruvate, 10% fetal bovine
serum, and 5% chicken serum. Viral reactivation from
latency was induced with 3mM n-butyrate, as previously
described [25]. DF-1 cells, obtained from a chicken fibro-
blast cell line, were cultured in a similar manner, in Dulbec-
co’s modified Eagle’s medium (DMEM) supplemented with
10% fetal calf serum (FCS) and 5% chicken serum (CS).
Chicken embryo fibroblasts (CEFs) were maintained in
DMEM (Lonza) supplemented with 2.5% FCS, 1.25% CS,
1% penicillin/streptomycin, 1% amphotericin B (Fungi-
zone) and 5% tryptose phosphate broth (TPB). CEFs were
prepared for propagation of the RB-1B virus strain, as previ-
ously described [63].
RACE-PCR and RT-PCR analysis
For RACE-PCR, total RNA was isolated with Trizol (Invi-
trogen) from reactivated MSB-1 (MSB-1R) or CEF RB-1B
cells, according to the manufacturer’s instructions, and was
treated with DNase (Promega). The cDNA ends were
amplified from 5 µg of RNA, with a GeneRacer kit (Invitro-
gen), according to the manufacturer’s instructions, and with
the primers shown in Table S1. Each 5¢ and 3¢ RACE-PCR
was performed as a nested-RACE-PCR with gene-specific
and nested gene-specific primers binding to sites a short dis-
tance apart (Fig. 2, Table S1).
For RT-PCR analysis, total RNA was isolated and cDNA
ends were amplified with the RNA+extraction kit
(Macherey-Nagel), according to the manufacturer’s instruc-
tions, using the primers shown in Table S1. For RT-PCR,
we reverse-transcribed 0.5 µg of RNA with a mixture of
oligo (dT) and random primers (Eurogentec) and the
Superscript-III reverse transcriptase (Invitrogen). The effi-
cacy of the DNase treatment of RNA was systematically
confirmed by PCR. A negative control for reverse tran-
scription (RT-) was systematically performed in the same
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conditions. The cDNAs generated were amplified by PCR
with the GoTaq DNA polymerase (Promega), according to
the manufacturer’s instructions, and with the primers listed
in Table S1. The cDNAs from PBLs (peripheral blood leu-
kocytes) have been described elsewhere [64].
For RACE-PCR and RT-PCR, the PCR products were
inserted into pGEM-T Easy (Promega) and sequenced by
GATC Biotech. All sequences were analysed by comparison
with the viral RB-1B sequence (GenBank accession number
RB-1B EF523390), with Geneious software (www.geneious.
com) and BLAST.
Quantitative RT-PCRs
To quantify ICP22 mRNA, mdv1-miR-M1-5p, mdv1-miR-
M4-5p and mdv1-miR-M5-3p expression levels (primers
shown in Table S1) via the 2 DD Ct method, the miScript
PCR System (Qiagen) was used. One microgram of total
RNA from CEF RB-1B, MSB-1 and MSB-1R cells was
reverse-transcribed using the miScript II RT Kit (Qiagen) in
a total volume of 20 µl, and 2 µl of a 1 : 10 dilution was used
for quantitative PCR, as recommended by the manufacturer
(Applied Biosystems). Glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH; primers shown in Table S1) and U6
(miScript; Qiagen) were used as reference genes for ICP22
and mdv1-miR experiments. All q-PCRs were performed on
the StepOnePlus Real-time PCR System (Applied Biosys-
tems) following the conditions recommended by the manu-
facturer, and dissociation curves were generated post-run.
Plasmid constructs
For the pGL3 luciferase reporter constructs, all the putative
promoter sequences were amplified with the primer pairs
described in Table S1 and inserted into the pGL3-Basic vec-
tor (Promega), as previously described [26].
The plasmids were purified with the NucleoBond Xtra Midi
kit (Macherey-Nagel), and the sequences of all inserts from
each construct were systematically verified (GATC Biotech).
The pGL3 plasmid, containing the promoter sequences of
ICP27 (pICP27-1000), ICP4 (pICP4-dis) and gk (pgk-
1000), was generated in previous studies [26, 62].
For the pcDNA3.1 expression contructs, the 540 bp ICP22
gene was first amplified by PCR from CEF RB-1B, with
the primer pairs indicated in Table S1. It was inserted into
the pGEMT-easy vector (Promega), and introduced into the
pcDNA3.1 vector (pcICP22) (Table S1). pcICP27 and
pcICP4 were produced in previous studies [7, 33]. pcICP22
vectors with mutations of the mdv1-miR-M1-5p, mdv1-
miR-M5-3p and mdv1-miR-M4-5p target sites were con-
structed by overlapping PCR (Table S1), from the pcICP22
vector (Table S1). The resulting amplicon was inserted into
the pcDNA3 expression vector to generate pcICP22-miRE-
M1m, pcICP22-miRE-M5m and pcICP22-miRE-M4m.
Dual luciferase reporter assays
Luciferase activity with pGL3 promoter constructs was
quantified with the dual-luciferase reporter assay system
(Promega), using one million MSB-1 cells transfected with
100 ng of pGL3 reporter construct, according to the manu-
facturer’s protocol. For the inter- and intra-assay standardi-
zation of luciferase activity, we systematically used 60 ng of
the control vector pCDNA-MLuc, from which the firefly
luciferase gene is expressed under the control of the CMV
promoter, and 2mg pRL-TK Renilla luciferase reporter con-
struct carrying the Renilla luciferase gene under the control
of the thymidine kinase promoter of HHV-1 [29]. Firefly
and Renilla luciferase activities were measured consecutively
24 h after transfection. Luminescence was measured with a
luminometer (Tristar2 luminometer; Berthold Technolo-
gies). Three independent experiments were carried out in
triplicate. Student’s t-test was used for statistical analysis.
The effects of ICP22 on IE promoters and the effects of IE
proteins on the ICP22 promoter were tested in adherent
DF-1 cells, plated in six-well dishes at a density of 5105
cells per well, and cotransfected in the presence of Lipofect-
amine 2000 (Invitrogen) with 500 ng of the promoter-lucif-
erase reporter vector, and 500 ng of the pcDNA3.1-ICP
expression vector or an empty pcDNA3.1 vector. Promoter
activities were normalized with respect to the corresponding
empty pcDNA3.1 (standardized to 1).
DNA isolation, bisulfite (BS) treatment and PCR
DNA was isolated with the DNeasy Blood and Tissue Kit
(Qiagen). BS treatment was performed with the EZ DNA
methylation – gold kit (Zymo Research), which converts
unmethylated cytosine residues into uracils, which are then
converted into thymidine residues during PCR. Nested PCR
was then performed with the primers indicated in Table S1,
with the Epimark Hot-Start Taq DNA polymerase (New
England Biolabs). Amplicons were inserted into the pGEM-
T easy vector (Promega) and the DNA insert was
sequenced.
Detection of ICP22 transcript and protein after
transient miR expression
Adherent DF-1 cells, plated in six-well dishes at a density of
5105 cells per well, were cotransfected in the presence of
Lipofectamine 2000 (Invitrogen) with 500 ng pcICP22,
pcICP22-miRE-M1m, pcICP22-miRE-M5m and pcICP22-
miRE-M4m and 25 ng pcDNA-mdv1-miR-M1, pcDNA-
mdv1-miR-M5, pcDNA-mdv1-miR-M4, pcDNA-mdv1-
miR-M8 or pcDNA-gga-miR-M155.
We used the Power SYBR Green Master system (Applied
Biosystems) to quantify ICP22 mRNA levels by the 2 DDCt
method. We subjected 1 µg of extracted RNA to reverse
transcription in a total volume of 20 µl, and 2 µl of a 1 : 10
dilution was used for quantitative PCR with specific pri-
mers, as indicated by the manufacturer (Table S1). GAPDH
was used as the reference gene. All qPCRs were performed
on the StepOnePlus Real-time PCR System (Applied Biosys-
tems), in the conditions recommended by the manufacturer,
and dissociation curves were generated post-run.
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Cells were lysed 24 h after transfection, and the proteins
were separated electrophoretically and blotted onto nitrocel-
lulose membranes. The membranes were blocked by incu-
bation with blocking buffer (Odyssey) and probed with a
rabbit polyclonal anti-ICP22 antibody or mouse anti-
GAPDH antibody, followed by monoclonal goat anti-rabbit
or anti-mouse infrared dye (IRD)-labelled secondary anti-
bodies (Odyssey). The immunoreactions of interest were
detected after excitation with light at wavelengths of 700
and 800 nm for the anti-mouse and anti-rabbit antibodies,
respectively. Protein levels were normalized with respect to
the corresponding empty pcDNA3.1 (standardized to 1).
Immunofluorescence
ICP22 proteins from CEF RB-1B and MSB-1 cells previ-
ously spotted with a Cytospin apparatus (Shandon, Thermo
Scientific), were detected with rabbit polyclonal anti-ICP22
antibodies. VP5 proteins were detected with the mouse anti-
vp5 mAb diluted 1 : 200.
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